FK1706, a novel non-immunosuppressive immunophilin: Neurotrophic activity and mechanism of action

European Journal of Pharmacology

Volumn 509, Issue 1, 2005, Pages 11-19

  Price, Raymond D ^a   Yamaji, Takayuki ^a   Yamamoto, Hiroko ^a   Higashi, Yasuyuki ^a   Hanaoka, Kaori ^a   Yamazaki, Shunji ^a   Ishiye, Masayuki ^a   Aramori, Ichiro ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a   Yanagihara, Takehiko ^b   Gold, Bruce G ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b Osaka Neurological Research Institute   (Japan)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Immunophilin; MAP kinase; Nerve growth factor; Neurite outgrowth

Indexed keywords

1,14 DIHYDROXY 12 [2 (4 HYDROXY 3 METHOXYCYCLOHEXYL) 1 METHYLVINYL] 23,25 DIMETHOXY 13,19 21,27 TETRAMETHYL 17 (2 OXOPROPYL) 11,28 DIOXA 4 AZATRICYCLO[22.3.1.0 4,9 ]OCTACOS 18 ENE 2,3,10,16 TETRONE; ANTIBODY; CYTOKINE; FK 1706; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; FK 506 BINDING PROTEIN 52; FK 506 BINDING PROTEIN 52 ANTIBODY; IMMUNOPHILIN; INTERLEUKIN 2; ISOPROTEIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE C INHIBITOR; PROTEIN INHIBITOR; RAF PROTEIN; RAS PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NERVE FIBER GROWTH; NEURITE; NEUROTROPISM; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 13844280494     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.12.023     Document Type: Article

References (29)

1. H.Y. Chang, K. Takei, A.M. Sydor, T. Born, F. Rusnak, and D.G. Jay Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin Nature 376 1995 686 690
2. J. Cheung-Flynn, P.J. Roberts, D.L. Riggs, and D.F. Smith C-terminal sequences outside the tetratricopeptide repeat domain of FKBP51 and FKBP52 cause differential binding to Hsp90 J. Biol. Chem. 278 2003 17388 17394
3. D.Y. Choi, J.J. Toledo-Aral, R. Segal, and S. Halegoua Sustained signaling by phospholipase C-gamma mediates nerve growth factor-triggered gene expression Mol. Cell. Biol. 21 2001 2695 2705
4. L.C. Costantini, D. Cole, P. Chaturvedi, and O. Isacson Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease Eur. J. Neurosci. 13 2001 1085 1092
5. A. Cuenda, J. Rouse, Y.N. Doza, R. Meier, P. Cohen, T.F. Gallagher, P.R. Young, and J.C. Lee SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 FEBS Lett. 364 1995 229 233
6. B.G. Gold Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders Expert Opin. Investig. Drugs 9 2000 2331 2342
7. B.G. Gold, and J.E. Villafranca Neuro immunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds Curr. Top. Med. Chem. 3 2003 1368 1375
8. B.G. Gold, M. Zeleny-Pooley, M.S. Wang, P. Chaturvedi, and D.M. Armistead A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration Exp. Neurol. 147 1997 269 278
9. B.G. Gold, V. Densmore, W. Shou, M.M. Matzuk, and H.S. Gordon Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506 J. Pharmacol. Exp. Ther. 289 1999 1202 1210
10. X. Guo, V.L. Dawson, and T.M. Dawson Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons Eur. J. Neurosci. 13 2001 1683 1693
11. Z. Han, D.L. Boyle, L. Chang, B. Bennett, M. Karin, L. Yang, A.M. Manning, and G.S. Firestein c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis J. Clin. Invest. 108 2001 73 81
12. E.J. Huang, and L.F. Reichardt Neurotrophins: roles in neuronal development and function Annu. Rev. Neurosci. 24 2001 677 736
13. L.M. Jensen Phenotypic differentiation of aphidicolin-selected human neuroblastoma cultures after long-term exposure to nerve growth factor Dev. Biol. 120 1987 56 64
14. A. Klettner, R. Baumgrass, Y. Zhang, G. Fischer, E. Burger, T. Herdegen, and K. Mielke The neuroprotective actions of FK506 binding protein ligands: neuronal survival is triggered by de novo RNA synthesis, but is independent of inhibition of JNK and calcineurin Brain Res., Mol. Brain Res. 97 2001 21 31
15. K. Lackey, M. Cory, R. Davis, S.V. Frye, P.A. Harris, R.N. Hunter, D.K. Jung, O.B. McDonald, R.W. McNutt, M.R. Peel, R.D. Rutkowske, J.M. Veal, and E.R. Wood The discovery of potent cRaf1 kinase inhibitors Bioorg. Med. Chem. Lett. 10 2000 223 226
16. U. Leli, A. Cataldo, T.B. Shea, R.A. Nixon, and G. Hauser Distinct mechanisms of differentiation of SH-SY5Y neuroblastoma cells by protein kinase C activators and inhibitors J. Neurochem. 58 1992 1191 1198
17. J. Liu, M.W. Albers, T.J. Wandless, S. Luan, D.G. Alberg, P.J. Belshaw, P. Cohen, C. MacKintosh, C.B. Klee, and S.L. Schreiber Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity Biochemistry 31 1992 3896 3901
18. P. LoPresti, W. Poluha, D. Poluha, E. Drinkwater, and A. Ross Neuronal differentiation triggered by blocking cell proliferation Cell Growth Differ. 3 1992 627 635
19. K. Mielke, and T. Herdegen JNK and p38 stresskinases-degenerative effectors of signal-transduction-cascades in the nervous system Prog. Neurobiol. 61 2000 45 60
20. A.K. Olsson, K. Vadhammar, and E. Nanberg Activation and protein kinase C-dependent nuclear accumulation of ERK in differentiating human neuroblastoma cells Exp. Cell Res. 256 2000 454 467
21. W.B. Pratt, A.M. Silverstein, and M.D. Galigniana A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37 Cell. Signal. 11 1999 839 851
22. R.D. Price, T. Yamaji, and N. Matsuoka FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway Br. J. Pharmacol. 140 2003 825 829
23. J.E. Reusch, P. Bhuripanyo, K. Carel, J.W. Leitner, P. Hsieh, D. DePaolo, and B. Draznin Differential requirement for p21ras activation in the metabolic signaling by insulin J. Biol. Chem. 270 1995 2036 2040
24. M.V. Sofroniew, C.L. Howe, and W.C. Mobley Nerve growth factor signaling, neuroprotection, and neural repair Annu. Rev. Neurosci. 24 2001 1217 1281
25. J.P. Steiner, T.M. Dawson, M. Fotuhi, C.E. Glatt, A.M. Snowman, N. Cohen, and S.H. Snyder High brain densities of the immunophilin FKBP colocalized with calcineurin Nature 358 1992 584 587
26. J.P. Steiner, G.S. Hamilton, D.T. Ross, H.L. Valentine, H. Guo, M.A. Connolly, S. Liang, C. Ramsey, J.H. Li, W. Huang, P. Howorth, R. Soni, M. Fuller, H. Sauer, A.C. Nowotnik, and P.D. Suzdak Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models Proc. Natl. Acad. Sci. U. S. A. 94 1997 2019 2024
27. K. Tanaka, N. Fujita, Y. Higashi, and N. Ogawa Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells Neurosci. Lett. 330 2002 147 150
28. C.J. Vlahos, W.F. Matter, K.Y. Hui, and R.F. Brown A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- one (LY294002) J. Biol. Chem. 269 1994 5241 5248
29. C. Zhang, J.P. Steiner, G.S. Hamilton, T.P. Hicks, and M.O. Poulter Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment J. Neurosci. 21 2001 RC156